Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Porin A (PorA) is a major class 1 outer membrane protein of Neisseria meningitidis serogroup B that functions as a cation-selective channel, facilitating the transport of small nutrients across the bacterial cell wall [1]. In vaccine pharmacology, PorA is typically delivered within Outer Membrane Vesicles (OMVs), which are spherical blebs released from the bacterial surface that contain a complex array of proteins and lipids [2]. These OMV-based antigens are critical for Neisseria meningitidis serogroup B prevention because the bacterium's polysaccharide capsule is poorly immunogenic and mimics human neural cell adhesion molecules, making protein-based targets essential for vaccine efficacy [3]. Vaccines targeting PorA and OMV proteins work by eliciting serum bactericidal antibodies that activate the host complement system to lyse the bacteria [4]. However, the high degree of sequence variability in the PorA surface loops necessitates the use of specific OMV strains or multi-component formulations to achieve broad protection against diverse meningococcal isolates [5]. The inclusion of OMVs in vaccines like Bexsero provides both a delivery system for PorA and an intrinsic adjuvant effect through residual bacterial components, though this can also contribute to increased reactogenicity in clinical settings [2, 5].
Induction of active immunity through the production of serum bactericidal antibodies that facilitate complement-mediated lysis of Neisseria meningitidis [4].
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Porin A (PorA) and associated outer membrane vesicle proteins of Neisseria meningitidis serogroup B (PorA/OMV).